Latest News and Press Releases

New York, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that Robert Califf, MD, MAAC, former Commissioner of the U.S. Food and Drug Administration and...

New York, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today celebrates the decision by the US Food and Drug Administration (FDA) to grant approval of a risdiplam...

New York, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 21 new grants with a total funding commitment of over $5 million toward...

Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational...

Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...

New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma,...

Portland, OR, July 18, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, and Others), By Route of...

New York, NY, Jan. 23, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) has  selected 15-year-old Leah Zelaya from Brooklyn, New York, as its 2023 MDA National Ambassador.  ...

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...